Frontier Medicines

We’re thrilled to welcome our co-founder Monique Silva Bobadilla for an intensive coaching session this week as we prepare for the official launch of our new School Leaders Program in 8 schools next week in Musanze and Rutsiro District respectively. Monique has over 20 years of experience in strategic leadership, talent development, change management and innovation. She brings invaluable expertise in building high-performing teams and fostering innovation. This week’s training will be crucial in finalizing the curriculum and tailoring it for primary school leaders. Monique’s collaboration will ensure our selected team of M2E Education Specialists are fully prepared.

We are pleased to welcome Dr. Daniel Erlanson to the Drug Hunter Scientific Advisory Board!   Dr. Erlanson brings over 25 years of experience in the biotech industry. Currently, he is Chief Innovation Officer of Frontier Medicines. Before that he co-founded and led chemistry at Carmot Therapeutics, Inc. Therapeutics, which collaborated with Amgen on the discovery of the first FDA-approved KRASG12C inhibitor, sotorasib. Carmot also put three of its own internally discovered drugs into the clinic before being acquired by Roche in early 2024.    Daniel is a widely recognized thought leader in fragment-based drug discovery (FBDD), serving as the editor of the popular Practical Fragments blog (https://lnkd.in/dStCAyZW), co-editor of two books on FBDD, and the inventor or author on over 70 granted US patents and peer-reviewed publications.   Daniel started his industry career at Sunesis Pharmaceuticals, Inc., where he co-invented the covalent disulfide tethering approach for finding fragments and advancing them to leads, enabling the discovery of drugs for targets once thought to be intractable for small molecules, such as KRAS. Daniel received his BA in chemistry from Carleton College, his PhD from Harvard University in the laboratory of Greg Verdine, and did postdoctoral work in Jim Wells’ group at Genentech.   We are privileged to have Daniel Erlanson on our Scientific Advisory Board, whose scientific leadership enhances Drug Hunter in our mission to empower the world’s scientists to make tomorrow’s medicines.   Welcome Daniel!